Orthocell Ltd (AU:OCC)
ASX:OCC
Want to see AU:OCC full AI Analyst Report?
OCC Stock Chart & Stats
AU$0.81
AU$0.07(4.58%)
At close: 4:00 PM EST
AU$0.81
AU$0.07(4.58%)
Day’s Range― - ―
52-Week RangeAU$0.70 - AU$1.60
Previous CloseN/A
Volume2.26M
Average Volume (3M)820.75K
Market Cap
AU$206.91M
Enterprise ValueAU$162.25M
Total Cash (Recent Filing)AU$44.37M
Total Debt (Recent Filing)AU$835.79K
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Aug 28, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding272,253,630
10 Day Avg. Volume747,972
30 Day Avg. Volume820,745
Financial Highlights & Ratios
PEG Ratio-3.76
Price to Book (P/B)18.08
Price to Sales (P/S)34.89
P/FCF Ratio-29.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.26Price Target Upside55.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.04
Revenue Forecast (FY)AU$12.23M
Bulls Say, Bears Say
Bulls Say
Top-line GrowthSustained revenue growth near 20% indicates expanding clinical adoption or market penetration of existing products. A growing top line improves the company’s ability to scale fixed-cost R&D and manufacturing, increasing the chance of reaching operating leverage and eventual profitability over several quarters.
Commercial Product FranchiseHaving a commercialized product (Remplir) gives Orthocell a revenue foundation and clinical footprint. A marketed therapy creates real-world clinical data, builds surgeon relationships, and forms a launch pad for adjacent indications and regulatory filings, supporting durable commercial growth if adoption continues.
Conservative LeverageVery low financial leverage provides balance-sheet flexibility to fund ongoing R&D and commercialization without immediate solvency pressure. It reduces fixed financing costs and lowers bankruptcy risk, allowing management to pursue clinical milestones and market expansion with less forced dilution.
Bears Say
Negative ProfitabilityPersistently negative margins and returns mean the business has not yet achieved unit economics needed for sustainable profits. Continued losses will pressure cash reserves and make future investment dependent on financing, increasing dilution risk unless gross margins or volume improve materially.
Cash-flow PressureNegative operating cash flow shows core operations are not self-financing; even with FCF growth, the company must rely on external funding to cover operating needs. Over the medium term this constrains strategic flexibility and can force dilutive equity raises or curtailed commercial investment if trends persist.
Execution & Market Access RisksRevenue depends heavily on regulatory/reimbursement outcomes, surgeon adoption and distribution expansion. With a small team (37 employees) and early commercial footprint, execution risk is material: delays in approvals, slow adoption, or limited distribution can materially slow durable revenue growth.
Orthocell Ltd News
OCC FAQ
What was Orthocell Ltd’s price range in the past 12 months?
Orthocell Ltd lowest share price was AU$0.70 and its highest was AU$1.60 in the past 12 months.
What is Orthocell Ltd’s market cap?
Orthocell Ltd’s market cap is AU$206.91M.
When is Orthocell Ltd’s upcoming earnings report date?
Orthocell Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 60 days.
How were Orthocell Ltd’s earnings last quarter?
Orthocell Ltd released its earnings results on Feb 23, 2026. The company reported -AU$0.021 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.021.
Is Orthocell Ltd overvalued?
According to Wall Street analysts Orthocell Ltd’s price is currently Undervalued.
Does Orthocell Ltd pay dividends?
Orthocell Ltd does not currently pay dividends.
What is Orthocell Ltd’s EPS estimate?
Orthocell Ltd’s EPS estimate is 0.
How many shares outstanding does Orthocell Ltd have?
Orthocell Ltd has 272,253,630 shares outstanding.
What happened to Orthocell Ltd’s price movement after its last earnings report?
Orthocell Ltd reported an EPS of -AU$0.021 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.333%.
Which hedge fund is a major shareholder of Orthocell Ltd?
Currently, no hedge funds are holding shares in AU:OCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orthocell Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.26 (55.56% Upside)
AU$1.26 (55.56% Upside)
Blogger Sentiment
Bullish
AU:OCC Sentiment 96%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$44.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
98.48%
12-Months-Change
Fundamentals
Return on Equity
-44.80%
Trailing 12-Months
Asset Growth
49.36%
Trailing 12-Months
Company Description
Orthocell Ltd
Headquartered in Murdoch, Australia, Orthocell Limited, established in 2006, operates as a regenerative medicine company focused on creating and bringing to market advanced cell therapies and biological medical devices. These innovations are designed to facilitate the healing of a range of bone and soft tissue injuries. The company's product lineup includes CelGro, a naturally derived collagen medical device engineered to augment surgical repair across various indications, including bone, peripheral nerves, tendons, and cartilage. Another key offering is Ortho-ATI, a specialized cell therapy developed for the treatment of chronic tendon injuries. Furthermore, Orthocell provides Ortho-ACI, an autologous chondrocyte implantation technique aimed at repairing articular cartilage defects in the knee and ankle. Its portfolio also features Striate+, a biodegradable collagen membrane employed for guided bone and tissue regeneration in dental applications, and Remplir, a collagen scaffold utilized for the restoration of peripheral nerves.
OCC Stock 12 Month Forecast
Average Price Target
AU$1.26
▲(55.56% Upside)
Technical Analysis
Cynata Therapeutics Limited
―
Living Cell Technologies
―
Mesoblast Limited
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Options Prices
Currently, No data available
---